8-KOther EventsExhibits & Filings

BeOne Medicines Ltd. 8-K Report, Corporate Update (Feb 6, 2018)

Filed February 6, 2018For Securities:ONCBEIGF

Summary

BeiGene, Ltd. (ONC) announced on February 5, 2018, the commercial availability of VIDAZA® (azacitidine for injection) in China. This marks a significant step for the company as VIDAZA is now accessible to patients in China diagnosed with specific hematological malignancies, including Intermediate-2 / High-risk myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) with 20-30% bone marrow blasts, and chronic myelomonocyte leukemia (CMML). The drug is marketed in China by BeiGene under an exclusive license from Celgene Corporation, highlighting a key strategic partnership. The availability of VIDAZA in the large Chinese market presents a substantial growth opportunity for BeiGene, potentially impacting its future revenue streams and market position within oncology therapeutics.

Key Highlights

  • 1BeiGene has launched VIDAZA® (azacitidine for injection) commercially in China.
  • 2VIDAZA is approved for Intermediate-2 / High-risk MDS, AML (20-30% blasts), and CMML patients in China.
  • 3The drug is marketed in China by BeiGene through an exclusive license from Celgene Corporation.
  • 4This launch represents BeiGene's entry into the significant Chinese oncology market with a new therapeutic option.
  • 5The event was announced via a press release filed as an exhibit to the 8-K.
  • 6The event date was February 5, 2018, with the filing date of February 6, 2018.

Frequently Asked Questions

VIDAZA (azacitidine for injection) is a nucleoside metabolic inhibitor approved for specific types of leukemia and myelodysplastic syndromes. Its commercial availability in China represents a significant market expansion opportunity for BeiGene, potentially driving future revenue and solidifying its presence in the Chinese oncology market.

VIDAZA is approved for patients in China with Intermediate-2 / High-risk myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) with 20-30% bone marrow blasts, and chronic myelomonocyte leukemia (CMML).

BeiGene is marketing VIDAZA in China under an exclusive license granted by Celgene Corporation.

While this 8-K filing does not contain specific financial data, the commercial launch of VIDAZA in China is expected to positively impact BeiGene's revenue growth by tapping into a large patient population and expanding its product portfolio in a key global market.